Skip to content

HPV Integration Testing for Cervical Cancer Screening

HPV(Human Papillomavirus) Integration Testing for Cervical Cancer Screening

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02576158
Enrollment
12000
Registered
2015-10-15
Start date
2015-04-30
Completion date
2020-04-30
Last updated
2017-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical Cancer, Cervical Intraepithelial Neoplasia

Brief summary

The primary objective is to determine the sensitivity and specificity of the HPV Integration-based cervical screening for detection of high-grade cervical intraepithelial neoplasia (CIN), using colposcopic inspection as the reference method. Lesions will be confirmed as malignant or CIN by colposcopic inspection and histopathologic examination.

Interventions

Sponsors

Huazhong University of Science and Technology
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
30 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

Women aged 30-65 years old Attending the China population-based organised cervical screening program

Exclusion criteria

1. Not providing informed consent 2. previously confirmed CIN, cervical cancer, or other malignancies 3. previous therapeutic procedure to cervix 4. pregnancy

Design outcomes

Primary

MeasureTime frame
the sensitivity and specificity of the HPV Integration-based cervical screening for detection of high-grade cervical intraepithelial neoplasia (CIN)with comparison to HPV testing or TCT14 Months

Countries

China

Contacts

Primary ContactDanhui Weng, MD, PhD
weng.dh@gmail.com+862783662681

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026